New Data Supports Initiation of Ph 3 RASolute 303 Registrational Trial of Daraxonrasib in 1L Metastatic Pancreatic Ductal Adenocarcinoma
“Patients living with pancreatic cancer have an urgent need for more effective and durable treatment options, and we are pursuing a bold vision to establish new global standards of care across treatment lines for this devastating disease,” said Mark A. Goldsmith M.D., Ph.D., chief executive officer and chairman of Revolution Medicines. “Daraxonrasib’s pioneering mechanism of action covering RAS cancer driver mutations broadly, and highly encouraging new clinical findings released today, together provide strong evidence of its potential to serve these patients. The promising clinical profile observed in investigational studies to date in both previously treated and treatment-naïve patients with pancreatic cancer compels initiation of our planned registrational study evaluating daraxonrasib as monotherapy and in combination with chemotherapy in the first line metastatic setting.”
Share:
More News
“The positive outcome of our pre-IND interactions with the FDA reinforces the development pathway for MaaT034 and supports its continued advancement toward the clinic. It also represents an important step in MaaT Pharma’s expansion into immuno-oncology, highlighting the broader potential of our first in class co-cultivated microbiome donor-independent platform across
“Patients with metastatic RAS G12D non-squamous NSCLC, occurring in approximately 4% of cases, represent an underserved population, with no approved targeted treatment options. Initial clinical data evaluating zoldonrasib in combination with standard of care pembrolizumab and platinum doublet chemotherapy in patients with previously untreated metastatic RAS G12D non-squamous NSCLC showed
“At Georgiamune, we are focused on uncovering novel mechanisms that control immune-cell function and translating that biology into first-in-class medicines across autoimmune disease and oncology,” said Samir N. Khleif, M.D., Founder and Chief Executive Officer of Georgiamune. “GIM-621 is one of multiple programs to emerge from that work, alongside three
“Our team’s outstanding execution has enabled us to rapidly advance three programs into the clinic in 2026 and make significant progress in developing next-generation IO, ADC and combination therapies. Together with our partner, Kelun-Biotech, we have achieved seven IND clearances to date, and by mid-2027, we expect more than 2,000